Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. INREBIC (fédratinib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

INREBIC (fédratinib)

Medicine - Posted on Oct 10 2024
Active substance (DCI)
  • fédratinib
history (2)
  • 9/25/24

    INREBIC (fedratinib) - Disease-related splenomegaly

    Summary of opinion. Favourable opinion for maintenance of reimbursement in “the treatment of disease-related splenomegaly or...
    CAV :
    54321
    icône flèche
  • 12/15/21

    INREBIC (fédratinib)

    Key points Favourable opinion for reimbursement in the treatment of disease-related splenomegaly or symptoms in adult patien...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EJ02
Manufacturer
BRISTOL-MYERS SQUIBB
Presentation

INREBIC 100 mg, gélule
flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 120 gélule(s) (CIP : 34009 302 326 2 0)

All our publications
    Blood and lymphatic diseases - miscellaneous Bone marrow diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
HSwBR0nr8CDJmSgA